AstraZeneca reduces earnings target; David Brennan steps down as CEO

Thursday 26 April 2012

AstraZeneca Plc has lowered its target for core earnings-per-share for 2012 following a steep decline in revenue in the first quarter – largely the result of the loss of patent protection on three key products. David Brennan, chief executive since 2006, is retiring effective 1 June.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom